AUTHORS
Danielle C. Kirkey, MD, Xiaojie Chu, PhD2, Melia Blankenfeld, BS3, Grace Hawkins4, Seungmin Shin5, Bruce Liu6, Rhonda E. Ries, MA7, Jack H. Peplinski, MSc8, Katherine Tarlock I, MD9, Sun Zeyu10, John Mellors, MD11, Wei Li, PhD12, Soheil Meshinchi, MD, PhD13
AFFILIATIONS
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States
2 University Of Pittsburgh, Pittsburgh, Pennsylvania, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States
5 University Of Pittsburgh, Pittsburgh, Pennsylvania, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States
7 Fred Hutchinson Cancer Center, Seattle, Washington, United States
8 Fred Hutchinson Cancer Center, Seattle, Washington, United States
9 Seattle Children's Hospital, Seattle, Washington, United States
10 University Of Pittsburgh, Pittsburgh, Pennsylvania, United States
11 University Of Pittsburgh, Pittsburgh, Pennsylvania, United States
12 University Of Pittsburgh, Pittsburgh, Pennsylvania, United States
13 Fred Hutchinson Cancer Center, Seattle, Washington, United States
ABSTRACT
Despite advancements in therapy for acute myeloid leukemia (AML), many patients will relapse or develop refractory disease with rapid disease progression. Targeted therapies in AML have been limited by significant overlap in expression with normal hematopoietic cells posing risk for hematopoietic toxicity. Gemtuzumab ozogamicin (GO), a CD33 antibody-drug conjugate (ADC), is routinely used in up-front treatment for AML; however, use in remission or as maintenance therapy is associated with worse outcomes due to preferential targeting of CD33 on healthy myeloid cells. Off-the-shelf AML-restricted targeted agents are urgently needed for patients, as rapid disease progression often limits the ability to receive therapies, such as CAR-T cells, due to time needed for manufacturing. CLEC2A has emerged as a promising leukemia-restricted target highly expressed in high-risk subtypes of AML without shared expression in normal hematopoietic cells. CLEC2A CAR-T therapy demonstrates robust anti-leukemia efficacy and is now moving to clinical trial for relapsed/refractory (R/R) AML. Here we show development and evaluation of a novel CLEC2A-targeting ADC providing an off-the-shelf therapy for patients with R/R AML.
To develop CLEC2A-targeting ADCs, we generated 8 novel CLEC2A Fab binders and evaluated each against CLEC2A+ and CLEC2A-negative paired isogenic cell lines (OCI-AML2, MOLM13 and MV4;11). CLEC2A Fab 1E3 emerged as the top binder candidate with high binding affinity (EC50: 6.1 nM) against CLEC2A+ cell lines and no binding in CLEC2A negative control cells. The CLEC2A 1E3 Fab was reformatted to an IgG antibody that demonstrated monomeric folding and resistance to aggregation. The novel CLEC2A 1E3 IgG antibody was then used to develop a CLEC2A-Tesirine ADC. Tesirine is a potent ADC linker-payload composed of a pyrrolobenzodiazepine (PBD) dimer warhead, a cleavable peptide linker and a PEG8 spacer, which when endocytosed leads to DNA crosslinking and subsequent blocking of cell division and tumor cell death. Incorporation of the CLEC2A 1E3 IgG into the Tesirine ADC retained binding capacity against recombinant CLEC2A and was internalized into the cytosol in CLEC2A+ cells, but not CLEC2A-negative cells assessed by pHrodo-deep red.
We then evaluated the antileukemic potential of the novel CLEC2A 1E3-Tesirine ADC against CLEC2A+ and negative paired isogenic cell lines with an isotype antibody (Ab1)-Tesirine ADC control and CLEC2A 1E3-IgG AAG control which carries the AAG mutation limiting its effector function. CLEC2A-positive and negative cell lines were cultured with the CLEC2A 1E3-Tesirine ADC or controls for 72 hours then cell viability was assessed by CellTiter Glo luminescent assay. Across all CLEC2A+ cell lines, the CLEC2A-Tesirine ADC resulted in robust target-dependent cell death with sub-nM IC50. In OCI-AML2, with endogenous CLEC2A surface expression, the CLEC2A-Tesirine ADC cleared AML with an IC50 0.13nM compared to an IC50 46.8nM in the CLEC2A knock-out OCI-AML2 cells (p=0.0009). We engineered CLEC2A-overexpressed (CLEC2A OE) cell lines via lentiviral transduction developed from MOLM13 an MV4;11 parental cells. In both CLEC2A OE cell lines, the CLEC2A-Tesirine ADC demonstrated remarkable anti-leukemia efficacy with an IC50 0.04nM for MOLM13 CLEC2A OE and IC50 0.02nM for MV4;11 CLEC2A OE, both >2 log fold lower than in their isogenic parental cells (p<0.001). Across all CLEC2A+ cell lines, the CLEC2A-Tesirine ADC resulted in >1000x fold higher killing than the CLEC2A-IgG AAG control. As the Tesirine linker-payload is highly potent, the Ab1-Tesirine control resulted in background killing only at high doses, which was equivalent to the CLEC2A-Tesirine ADC response in the CLEC2A-negative cells.
CLEC2A has emerged as a true leukemia-restricted target in AML without shared expression in normal hematopoiesis and absent in nearly all healthy tissues allowing for effective anti-leukemia efficacy without target-dependent hematopoietic toxicity. While CLEC2A CAR-T cells are moving to clinical trial, we sought to develop an off-the-shelf CLEC2A-targeting therapy providing an alternative strategy for patients unable to receive CAR-T cell therapy. Here we detail the development of a novel CLEC2A-targeting ADC with highly potent anti-leukemia efficacy providing an urgently needed therapeutic option for relapsed/refractory AML with the potential to be utilized as maintenance therapy post-transplant to reduce the risk of relapse.
DISCLOSURES
Danielle C. Kirkey, MD: No relevant conflicts of interest to declare.